In this episode of AWM Insights, Chief Investment Officer Justin Dyer and Portfolio Manager Mena Hanna take a close look at IPOs, breaking down what an initial public offering truly means and how it fits—or fails to fit—into a disciplined, generational wealth strategy. They dig into headline-makers like SpaceX and discuss the realities behind IPO “pops,” market timing, and the long-term results data shows for investors. For families thinking beyond the next big story, Justin and Mena share expert perspectives on where real opportunities live and why chasing IPO hype rarely leads to lasting wealth. If you want to understand the true game plan for building and protecting multi-generational prosperity, this episode is essential listening.Chapters(00:00) Understanding IPOs and Public Markets(01:32) How IPOs Work and Access Points(04:40) IPO Day Pops and Lockup Periods(07:31) Challenges of Wealth Building via IPOs(09:36) Systematic Investing in Private and Public Markets(11:00) Early-Stage Access versus Pre-IPO Hype(13:00) Portfolio Strategy and Avoiding Forced BuyingConnect with Us• Call or text us: 626-862-0355• Website: https://www.athletefamilyoffice.com/• YouTube: https://www.youtube.com/channel/UCc1NxpK21N1vKWEExC45YEA• LinkedIn: https://www.linkedin.com/company/awmcapital/• Instagram: https://www.instagram.com/awmcapital/• X: https://twitter.com/awmcapital• Facebook: https://www.facebook.com/awmcapital/

In this episode of "In the Interim…", Dr. Scott Berry is joined by Dr. Will Meurer, professor of Emergency Medicine and Neurology at the University of Michigan, for an in-depth discussion of the ICECAP trial’s adaptive Bayesian design. The discussion breaks down the scientific rationale for hypothermia after cardiac arrest, critiques legacy studies, and explores the justification for including both shockable and non-shockable rhythm types. The episode provides a detailed account of ICECAP’s methodological strategies: a weighted mRS primary endpoint, Bayesian adaptive trial structure, response-adaptive randomization (governed by strict allocation guardrails), a unique Bayesian model for duration-response, and futility rules. The trial’s development is described in the context of the ADAPT-IT initiative, an FDA/NIH partnership, and the operational leadership of the MUSC Data Coordinating Center. Results are pending publication which will be highlighted in a future episode of “In the interim…”.Key HighlightsRationale for exploring duration of hypothermia after cardiac arrest with review of prior evidence.Enrollment of shockable and non-shockable populations to address clinical uncertainty.Primary endpoint: weighted mRS, independently developed for ICECAP.Bayesian adaptive design with response-adaptive randomization, interim analyses, and allocation guardrails.Management of missing data with multiple imputation from 30-day outcomes.For more, visit us at https://www.berryconsultants.com/

On this episode of Resilience Talk, Paul Spencer unpacks what he has been learning about the sales process through a newer business venture, and why the language your customer uses is often the difference between a yes and a "we already have that." He works through the yes/no/maybe pipeline, how he's using AI to turn customer nuggets into sales assets, and what "sell before you can do" actually looks like in practice.Connect with PaulWebsite: https://www.secondnature.solutions/Subscribe to the newsletter: https://www.secondnature.solutions/joinLinkedIn: https://www.linkedin.com/in/paul-spencer-7252118/Chapters[00:00] Intro: A new business, a new sales reality[00:35] FF&E vs. CapEx: Learning the language that shifted my pitch[08:31] Same business, same costs, same buyer, just a different key[10:18] Yes or no, never maybe: Why maybes drain the pipeline[22:04] Turning customer nuggets into sales assets with Claude[28:40] The S-curve and product-market fit: Why $1M doesn't sell like $20M[37:21] Sell before you can do: Discovery-led selling and the OODA loop[43:22] Predictable, consistent, improving: Closing thoughts

In this milestone 50th episode of Travel Buddy, Rachel Satow, and Ian Andersen reflect on the journey of the podcast and the evolution of the travel and loyalty industry. From memorable guests and standout episodes to behind-the-scenes insights on how their approach and the industry itself have matured, you’ll hear the inside story of what goes into building a successful travel podcast. The conversation features honest reflections, plenty of humor, and invaluable lessons learned along the way such as game-changing innovations around AI, product development, and partnership building. If you’re curious about what’s next for travel rewards or want a genuine look at the people shaping this space, this episode is not to be missed.Chapters(00:00) Reflections on 50 Episodes and Show Growth(01:00) Evolving Conversations and Deeper Industry Insights(03:00) Hosting Diverse Guests and Partner Highlights(07:00) Platform Innovation and AI Integration(14:00) Maturing Audience and Market Expectations(16:00) Shifting Focus to Internal and External Experts(24:00) Value, Camaraderie, and Looking AheadConnect with SwitchflyWebsite: https://www.switchfly.com/LinkedIn: https://www.linkedin.com/company/switchfly/X: https://twitter.com/switchflyYouTube: https://www.youtube.com/@SwitchflyOfficial

In this episode of "In the Interim…", Dr. Scott Berry details the design, execution, and results of the multi-platform randomized clinical trial (mpRCT) pioneered during the COVID-19 pandemic. He describes how REMAP-CAP, ATTACC, and ACTIV-4a—each developed independently—pooled data prospectively for joint analysis to address therapeutic anticoagulation in hospitalized COVID-19 patients. Scott outlines the operational rigor required to harmonize endpoints, establish monthly adaptive analyses, and stratify patients by disease severity and D-dimer level. He examines the unified Bayesian hierarchical modeling approach, dynamic borrowing across strata, and the process for simultaneous DSMB reviews coordinated across all platforms. The mpRCT framework enabled real-time, evidence-based adaptations and rigorous distinction of treatment effect by patient subgroup. Results were incorporated into clinical guidelines because prospectively specified analysis revealed benefit for moderate patients and futility or harm for severe patients—findings that would have been missed by standard post hoc pooling.Key HighlightsIntegration of REMAP-CAP, ATTACC, and ACTIV-4a under a prospectively unified analysis plan.Primary endpoint and stratified patient subgroups defined in advance.Monthly adaptive analyses using a shared Bayesian hierarchical model.Simultaneous oversight by joint statistical and DSMB committees.Superiority of therapeutic anticoagulation in moderate, non-critically ill groups; futility and possible harm in severe patients.mpRCT model established a framework for future global multi-platform trials.For more, visit us at https://www.berryconsultants.com/